Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nortriptyline effect on apnea-hypopnea index after uvulopalatopharyngoplasty
IRCT20230614058482N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nortriptyline in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Tehran University of Medical Sciences. Primary endpoint: apnea hypopnea index. Started Sep 2023; status: completed.
02
Drugs
nortriptyline
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on IRCT20230614058482N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230614058482N1.